Schering-Plough’s Fred Hassan: An Interview With “The Pink Sheet”
Executive Summary
After unveiling Schering-Plough's R&D pipeline in November, CEO Fred Hassan talked with "The Pink Sheet" in mid-December about balancing primary and specialty care portfolios, fixed-term limits for future FDA commissioners, licensing opportunities and more.
You may also be interested in...
Schering-Plough's Saphris Hits FDA Roadblock With "Complete Response"
Agency says there is no need for additional clinical trials for the atypical antipsychotic.
Schering Telescope Points To 5 R&D “Stars,” But TRA Shines Brightest
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on
As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: